One-year parasitological screening of stray dogs and cats in County Dublin, Ireland

Andres, Garcia-Campos; Power, Conor; O’Shaughnessy, Joyce; Browne, Clare M.; Lawlor, Amanda; McCarthy, Grainne; O’Neill, Emma; Waal, Theo de

doi:10.1017/s0031182018002020

Cited by 12 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This differentiation may be important in certain geographical regions where dogs have been found to be primarily infected with U. stenocephala, e.g. in Spain, UK, Ireland and Greece [3,[17][18][19]. Monthly administered products that include a macrocyclic lactone are particularly beneficial in that they not only provide control of most important intestinal parasitic nematodes of dogs but also provide control of the clinically important cardiopulmonary nematodes [2].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs

et al. 2020

View full text Add to dashboard Cite

Background: Ancylostomatids ('hookworms') are among the most important zoonotic nematode parasites infecting dogs worldwide. Ancylostoma caninum and Uncinaria stenocephala are two of the most common hookworm species that infect dogs. Both immature and adult stages of hookworms are voracious blood feeders and can cause death in young dogs before infection can be detected by routine fecal examination. Hence, treatment of both immature and adult stages of hookworms will decrease the risk of important clinical disease in the dog as well as the environmental contamination caused by egg-laying adults, which should reduce the risk of infection for both dogs and humans. The studies presented here were conducted to evaluate the efficacy of a novel, oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio ™), against induced larval (L 4), immature adult (L 5) and adult A. caninum, and adult U. stenocephala infections in dogs. Methods: Eight negative-controlled, masked, randomized laboratory studies were conducted. Two separate studies were conducted against each of the target parasites and stages. Sixteen or 18 purpose bred dogs, 8 or 9 in each of the two treatment groups, were included in each study. Dogs experimentally infected with the target parasite were dosed once on Day 0 with either placebo tablets or Simparica Trio ™ tablets to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel (as pamoate salt). Timing of dosing relative to parasite inoculation allowed for efficacy to be evaluated primarily against the target parasite stage. Worm counts were conducted 7 or 8 days after treatments during necropsy. Efficacy was based on the number of worms recovered at necropsy compared to placebo control. Results: Based on geometric mean worm counts, efficacy of Simparica Trio ™ was ≥ 98.4% against L 4 larval stage of A. caninum, ≥ 99.8% against immature adult (L 5) A. caninum, and 100% against adult A. caninum and adult U. stenocephala. Conclusions: These studies confirm the efficacy of a single oral dose of a novel, chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio ™) against L 4 larval and immature adult (L 5) A. caninum, and adult A. caninum and U. stenocephala infections in dogs.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The heteroxenous life-cycle relies on gastropods as intermediate hosts, and different prey species play a role in transmission as paratenic hosts [7,8]. Most reports on A. abstrusus prevalence in cats originate from Europe, ranging between 0.1 and 10.7% in northern and central Europe [9][10][11][12][13][14][15][16] and between 8.0 and 27.3% in eastern and southern Europe [5,[17][18][19][20], but studies were also conducted in Asia (e.g. Qatar 7.5% [21]), the Americas (e.g.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Bravecto® Plus spot-on solution for cats (280 mg/ml fluralaner and 14 mg/ml moxidectin) for the prevention of aelurostrongylosis in experimentally infected cats

et al. 2021

View full text Add to dashboard Cite

Background The feline lungworm Aelurostrongylus abstrusus affects the lower respiratory tract in cats worldwide. As infections may lead to chronic respiratory changes or even death, preventive treatment in cats with outdoor access is warranted. Methods The preventive efficacy of a spot-on solution (Bravecto® Plus spot-on solution for cats, MSD) against cat aelurostrongylosis was evaluated using three different preventive treatment regimes in a negative controlled, randomized and partially blinded laboratory efficacy study with 31 purposed-bred cats. The minimum recommended dose of 2.0 mg moxidectin + 40 mg fluralaner/kg bodyweight was applied once 12 (Group [G]1), 8 (G2) or 4 (G3) weeks before experimental infection with 300 third-stage larvae (L3) of A. abstrusus. Another group served as untreated control (G4). Individual faecal samples were analysed as of day 30 post infection (pi) to monitor larvae excretion. Necropsy was performed at days 47–50 pi. The lungs were examined macroscopically for pathological findings and (pre-)adult worms were counted to assess preventive efficacy. Results Beginning at day 32–40 pi, all cats of the control group were constantly shedding larvae of A. abstrusus, whereas only one animal of G1 excreted larvae at several consecutive days. In addition, two cats of G1 and G3 and three of G2 were positive on a single occasion. The geometric mean (GM) of the maximum number of excreted larvae was 7574.29 in the control group compared to 1.10 (G1), 1.19 (G2) and 0.53 (G3), resulting in a GM reduction of > 99.9% in all treatment groups. All lungs of the control animals showed severe or very severe alterations at necropsy, while in 94.44% of the treated cats lung pathology was rated as absent or mild. The GM number of (pre-)adult A. abstrusus retrieved from the lungs was 26.57 in the control group, 0.09 in G1 and 0.00 in G2 and G3. Thus, GM worm count reduction was 99.66% in G1 and 100% in G2 and G3. Conclusions A single application of Bravecto® Plus spot-on solution at a dose of 2.0 mg moxidectin + 40 mg fluralaner/kg bodyweight reliably prevents cat aelurostrongylosis for at least 12 weeks.

show abstract

“…The hookworm U. stenocephala is a common intestinal parasite of domestic dogs in regions with a cold climate. The prevalence rates of U. stenocephala can vary in different regions, as a function of climate, living conditions, quality of veterinary care, and diagnostic resources [11,12]. In Russia, this species is not as frequently recorded in dogs as is T. canis.…”

Section: Discussionmentioning

confidence: 99%

A retrospective study of Uncinaria stenocephala in domestic dogs: Age, sex distribution, and risk factors

Shchelkanov

Табакаева

Fomenko³

et al. 2021

Vet World

View full text Add to dashboard Cite

Background and Aim: Uncinaria infection often appears in domestic dogs. In the present study, parasitological examination of fecal samples from 782 dogs were analyzed for the presence of Uncinaria stenocephala. Materials and Methods: Fecal samples were analyzed by means of a standardized flotation method using a saturated salt solution containing NaNO3 (specific gravity 1.38), with a centrifugation step. Results: The highest prevalence rates were found among young adult dogs (8.3%), followed by puppies (5.4%); the lowest prevalence rates were found in dogs older than 3 years (4.3%). The prevalence was 5.8% among female dogs and 7.2% in male dogs. Coinfections with roundworms and protozoan parasites were frequently observed in U. stenocephala-positive dogs (15%). In total, three types of coinfections were registered. Coinfection of U. stenocephala + Sarcocystids oocysts was recorded in 19.1% of the dogs (n=10). This may relate to higher prevalence of S. oocysts in dogs (n=153; 19.5%). There were two cases of coinfection of U. stenocephala + Toxocara canis (3.9%), which may relate to low prevalence of T. canis (3.9 %). One case of coinfection of Dipylidium caninum + U. stenocephala (0.1%) also appeared. Conclusion: The present study showed that male dogs and young dogs were most susceptible to U. stenocephala infection.

show abstract

One-year parasitological screening of stray dogs and cats in County Dublin, Ireland

Cited by 12 publications

References 42 publications

Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs

Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs

Efficacy of Bravecto® Plus spot-on solution for cats (280 mg/ml fluralaner and 14 mg/ml moxidectin) for the prevention of aelurostrongylosis in experimentally infected cats

A retrospective study of Uncinaria stenocephala in domestic dogs: Age, sex distribution, and risk factors

Contact Info

Product

Resources

About